Seagen Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

Wall Street analysts have given Seagen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seagen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Seagen saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 2,400,000 shares, a decrease of 19.5% from the June 30th total of 2,980,000 shares. Based on an average trading volume of 804,500 shares, the short-interest ratio is presently 3.0 days. Approximately 1.3% of the company's shares are short sold.
View Seagen's Short Interest.

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Seagen.

Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings data on Thursday, July, 29th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.14. Seagen had a net margin of 25.06% and a trailing twelve-month return on equity of 19.02%.
View Seagen's earnings history.

Seagen's stock was trading at $104.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SGEN shares have increased by 56.8% and is now trading at $163.83.
View which stocks have been most impacted by COVID-19.

15 equities research analysts have issued 12-month price targets for Seagen's stock. Their forecasts range from $145.00 to $254.00. On average, they expect Seagen's share price to reach $184.75 in the next year. This suggests a possible upside of 12.8% from the stock's current price.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Halozyme Therapeutics (HALO).
View all of SGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.51%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Pinnacle Associates Ltd. (0.18%), New York State Common Retirement Fund (0.08%), Victory Capital Management Inc. (0.08%) and Alliancebernstein L.P. (0.04%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen.

SGEN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Handelsbanken Fonder AB, Oregon Public Employees Retirement Fund, Alliancebernstein L.P., Advisor Group Holdings Inc., Sumitomo Mitsui Trust Holdings Inc., Pinnacle Associates Ltd., and Oppenheimer & Co. Inc.. Company insiders that have sold Seagen company stock in the last year include Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

SGEN stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, EFG Asset Management Americas Corp., IFM Investors Pty Ltd, New York State Common Retirement Fund, Arizona State Retirement System, Advisors Asset Management Inc., Victory Capital Management Inc., and Tuttle Tactical Management.
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $163.83.

Seagen has a market capitalization of $29.81 billion and generates $2.18 billion in revenue each year. The biotechnology company earns $613.67 million in net income (profit) each year or $3.30 on an earnings per share basis.

Seagen employs 2,092 workers across the globe.

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

Seagen was founded in 1998.

The official website for Seagen is www.seattlegenetics.com.

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]